For example, ASO-based drugs have already shown clinical success in other neurological and cardiovascular conditions, suggesting that RNA-based therapeutics could provide feasible intervention strategies for modulating GATA2/IRF7-driven gene networks in stroke (Nitschke and Minassian, 2024; Dhuri et al., 2020). This evidence concerns the gene IRF7 and Stroke.